دورية أكاديمية
PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
| العنوان: | PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma. |
|---|---|
| المؤلفون: | Zantut-Wittmann DE; Endocrinology Division, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil. Electronic address: zantutw@unicamp.br., Barreto IS; Department of Pathology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil., Laus AC; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., Moreno DA; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., Moma CA; Endocrinology Division, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil., Maia FFR; Endocrinology Division, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil., Assumpção LVMD; Endocrinology Division, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal. |
| المصدر: | Molecular and cellular endocrinology [Mol Cell Endocrinol] 2023 Jun 15; Vol. 570, pp. 111931. Date of Electronic Publication: 2023 Apr 16. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: North Holland Publishing Country of Publication: Ireland NLM ID: 7500844 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8057 (Electronic) Linking ISSN: 03037207 NLM ISO Abbreviation: Mol Cell Endocrinol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Limerick : North Holland Publishing Original Publication: Amsterdam, North-Holland. |
| مواضيع طبية MeSH: | Carcinoma, Papillary*/pathology , Thyroid Neoplasms*/pathology , Adenocarcinoma, Follicular*/genetics, Humans ; Female ; Adult ; Middle Aged ; Male ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Prognosis ; B7-H1 Antigen/genetics ; Iodine Radioisotopes/therapeutic use ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/drug therapy ; Thyroid Cancer, Papillary/genetics ; Retrospective Studies |
| مستخلص: | Objectives: MCL-1 and PD-L1 proteins are related to carcinogenesis mechanisms in differentiated thyroid carcinoma(DTC). Tumor antigens stimulate the expression of PD-1 in immune cells, which binds to PD-L1 of tumor cells, inducing immune escape from the tumor. MCL-1, an anti-apoptotic member of the BCL-2 family, is necessary for the survival of T and B lymphocytes and has a high oncogenic potential. We aim to evaluate the clinical utility and relevance of MCL-1 and PD-L1 in the long-term prognosis of DTC. Methods: 120 DTC patients after total thyroidectomy and radioiodine therapy followed for a minimum of 2 years were included. Demographic features, tumor histopathology, persistence/recurrence risk, factors associated with outcome, initial response to therapy, persistence or disease-free at the follow-up were related to MCL-1 and PD-L1 immunohistochemical expression and BRAFV600E mutation. Results: 100(83.3%) were women, 46.64 ± 16.73 years old at diagnosis; 37(30.8%) patients were at high, 45(37.5%) of intermediate and 38(31.7%) of low disease recurrence/persistence risk. At the end of follow-up of 124.86 ± 65.36 months, 48(42.5%) had persistent disease. 103(85.8%) patients had papillary thyroid carcinoma (PTC), 17(14.2%) follicular thyroid carcinoma (FTC). In PTC, moderate/strong PD-L1 and MCL-1 expressions were associated to BRAFV600E (p=0.0467; p=0.0044). PD-L1 was also associated with tall cell subtype (p=0.0274). In FTC, weak PD-L1 expression was associated to the largest nodule diameter (p=0.0100). Strong/moderate PD-L1 expression was associated to T2 and the weak expression with T3 in TNM classification (p=0.0490). Moderate MCL-1 expression was associated to smoking (p=0.0350). Conclusions: PDL-1, marker of progression of tumor cells and MCL-1, anti-apoptotic marker, were associated with PTC carrying BRAFV600E mutation, while PDL-1 was associated with more aggressive PTC subtype. MCL-1 and PD-L1 could be useful in composing a panel to assess the prognosis of PTC patients. On the other hand, both markers seemed to have lower relevance to FTC patients. Competing Interests: Declaration of competing interest The authors have nothing to declare. (Copyright © 2023 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: MCL-1; PD-L1; Thyroid carcinoma; Tumor markers |
| المشرفين على المادة: | 0 (Myeloid Cell Leukemia Sequence 1 Protein) 0 (B7-H1 Antigen) 0 (Iodine Radioisotopes) |
| تواريخ الأحداث: | Date Created: 20230418 Date Completed: 20230522 Latest Revision: 20230522 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.mce.2023.111931 |
| PMID: | 37072108 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1872-8057 |
|---|---|
| DOI: | 10.1016/j.mce.2023.111931 |